Raptor Pharmaceuticals (RPTP) has been the subject of several positive comments from analysts this week. Since I am currently underweight biotech and the company seems to have good growth prospects, I decided to take a flyer on this small biotech firm today.
Key recent comments/positives for Raptor:
- Canaccord Genuity just reiterated its "Buy" rating on the shares. The analyst firm has a $11 price target on RPTP, more than twice its current price.
- Oppenheimer also put out positive comments on the shares advising to buy on weakness.
- JMP Securities echoed the same theme on the shares on December 24th.
- The company recently signed a $50 million loan agreement with HealthCare Royalty Partners to help fund the commercialization of PROCYSBI(TM), a potential treatment of nephropathic cystinosis. This shows confidence that this compound will be approved by the FDA sometime in the second quarter.
Raptor Pharmaceuticals is a small biotechnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise.
4 additional reasons RPTP is a worthy highly speculative play at just over $5 a share.
- The stock definitely has analyst support. The median price target on the shares by the four analysts that cover the stock is $10 a share. Price targets ranged from $7 to $12 a share, all significantly above the current stock price.
- Unlike a lot of small biotechs, Raptor has actual current revenues totaling some $26mm in FY2012. That is projected to double in FY2013 on the back of the approval of Procysbi.
- Earnings are heading in the right direction. The company lost 80 cents a share in FY2011, but is tracking to just a half a dollar a share loss in FY2012. Raptor is expected make a dime a share in FY2013.
- The company already had net cash on the books before the $50mm loan agreement, so liquidity is not a current concern. It also seems to have some technical support in the $4.50 a share level (See chart)
Note: I decided to do a buy-write on this position today to mitigate some downside risk. I bought shares at the $5.25 a share level while simultaneously selling the August $7.50 calls for $1.10.